Cost-effectiveness of abemaciclib | BCTT
Hormone receptor positive (HR+) breast cancer represents 70% of all primary breast cancers. Adjuvant endocrine therapy reduces the recurrence rate in these patients, however a significant proportion still experiences recurrence...
Conclusions: The addition of abemaciclib to adjuvant endocrine therapy in all high-risk ER , HER2- EBC patients is not cost-effective. However, using MRD detection to justify the addition of abemaciclib treatment dominates standard treatment in this cost-effectiveness analysis. Further evaluation of MRD detection in EBC by means of prospective...
Is another class of molecular targeted therapy an appropriate decision as the next treatment for progressive disease with initial molecular targeted therapy for luminal advanced/metastatic breast cancer? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36823129/
The sequential use of different classes of MTA did not affect the TTF of another MTA. Therefore, mTOR inhibitor + exemestane is a favorable treatment option administered after CDK4/6 inhibitor...
Conclusions: The sequential use of different classes of MTA did not affect the TTF of another MTA. Therefore, mTOR inhibitor exemestane is a favorable treatment option administered after CDK4/6 inhibitor hormone therapy. The CDK4/6 inhibitor hormone therapy is also suitable for patients previously treated with mTOR inhibitor exemestane....
Nanoparticle-mediated cancer cell therapy: basic science to clinical applications - Cancer and Metastasis Reviews
Source : https://link.springer.com/article/10.1007/s10555-023-10086-2
Every sixth person in the world dies due to cancer, making it the second leading severe cause of death after cardiovascular diseases. According to WHO, cancer claimed nearly 10 million...
Conclusions: This review summarises the extant understanding and the work done in this area to pave the way for physicians to accelerate the use of hybrid mode of treatments by leveraging the use of various nanoparticles.
Abemaciclib: A Review in Early Breast Cancer with a High Risk of Recurrence - Targeted Oncology
Source : https://link.springer.com/article/10.1007/s11523-023-00952-y
Abemaciclib [Verzenio® (USA) or Verzenios® (EU)] is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor approved in combination with adjuvant endocrine therapy for patients with hormone receptor positive (HR+), human...
Conclusions: Abemaciclib in combination with standard endocrine therapy is a valuable additional treatment option for patients with HR , HER2−, node-positive early breast cancer with a high risk of recurrence.
Thromboembolism profiles associated with cyclin-dependent kinase 4/6 inhibitors: a real-world pharmacovigilance study and a systematic review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36794339/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: CDK4/6i had different profiles of thromboembolism. Palbociclib, abemaciclib, or trilaciclib increased the risk of VTE. Ribociclib and abemaciclib showed a weak association with the risk of ATE.